In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

In this webinar you’ll learn how these very different technologies serve specific needs and how creating a testing strategy that employs many of these different methodologies can provide the information clinicians need to make the best treatment decisions for critically ill patients.

Speakers:

John Longshore
Director of Molecular Pathology
Carolinas Pathology Group

Harry Hwang
Director of Molecular Pathology
Phenopath Laboratories